Kiniksa Pharmaceuticals International, plc (KNSA)
NASDAQ: KNSA · Real-Time Price · USD
21.37
+0.80 (3.92%)
Apr 25, 2025, 4:00 PM EDT - Market closed

Company Description

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide.

Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1α, IL-1β-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation.

Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024.

The company was incorporated in 2015 and is based in London, the United Kingdom.

Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International, logo
Country United Kingdom
Founded 2015
IPO Date May 24, 2018
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 315
CEO Sanj Patel

Contact Details

Address:
23 Old Bond Street, Floor 3
London, WIS 4PZ
United Kingdom
Phone 781 431 9100
Website kiniksa.com

Stock Details

Ticker Symbol KNSA
Exchange NASDAQ
Share Class Class A Shares
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001730430
CUSIP Number G5269C101
ISIN Number BMG5269C1010
SIC Code 2834

Key Executives

Name Position
Sanj K. Patel Chief Executive Officer and Chairman of the Board
Joseph Pirrello Chief Business Officer
Aaron Young Chief Intellectual Property Officer
Randy Perrin Group Vice President and Global Medical Affairs

Latest SEC Filings

Date Type Title
Apr 23, 2025 SCHEDULE 13G/A Filing
Apr 23, 2025 8-K Current Report
Apr 21, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 21, 2025 ARS Filing
Apr 21, 2025 DEF 14A Other definitive proxy statements
Apr 21, 2025 144 Filing
Apr 14, 2025 144 Filing
Apr 10, 2025 PRE 14A Other preliminary proxy statements
Apr 4, 2025 SCHEDULE 13G Filing
Mar 17, 2025 144 Filing